Find policies, billing codes, payers, states, and providers
CPT 87513: H. pylori Detection with Clarithromycin Resistance, Amplified NA Probe
CPT code 87513 covers a molecular diagnostic assay that detects Helicobacter pylori infection and determines clarithromycin resistance using an amplified nucleic acid probe technique. This code is important nationally because H. pylori is a common pathogen linked to peptic ulcer disease and gastric inflammation, and detection of clarithromycin resistance informs antibiotic selection and stewardship. The test supports targeted therapy and can affect clinical outcomes and antimicrobial resistance management across care settings.
Key payers analyzed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find information about clinical context, typical sites of service, and payer coverage considerations. The publication provides benchmarks and reimbursement context where available, summarizes coding and billing implications for laboratory and hospital settings, and highlights policy and utilization trends relevant to molecular infectious-disease testing. Data not available in the input will be noted as such in the relevant sections.
Customize your policy alerts
Sign up for cpt 87513 policy alerts
Get alerted when payer policies referencing 87513 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 87513 describes a laboratory test that detects Helicobacter pylori infection using an amplified nucleic acid probe technique and also identifies resistance to the antibiotic clarithromycin. The service type is a molecular diagnostic assay for infectious disease detection and antimicrobial resistance. The typical site of service is a clinical laboratory or hospital laboratory performing molecular testing on patient specimens.